COVID-19 UPDATE

Contact

BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

Financials & Filings

Filing date	Description	Form	Filing Group	Issuer	View
Feb 16, 2021	Annual filing director officer or owner of more than ten percent.	5	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-21-000022.pdf 0001103021-21-000022.rtf 0001103021-21-000022.xls
Feb 12, 2021	An amendment to the SC 13G filing	SC 13G/A	Other	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001193805-21-000194.pdf 0001193805-21-000194.rtf 0001193805-21-000194.xls
Feb 08, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-21-000020.pdf 0001103021-21-000020.rtf 0001103021-21-000020.xls
Feb 02, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-21-000014.pdf 0001103021-21-000014.rtf 0001103021-21-000014.xls
Feb 02, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-21-000016.pdf 0001103021-21-000016.rtf 0001103021-21-000016.xls
Feb 02, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-21-000012.pdf 0001103021-21-000012.rtf 0001103021-21-000012.xls
Feb 02, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-21-000018.pdf 0001103021-21-000018.rtf 0001103021-21-000018.xls
Jan 29, 2021	An amendment to the SC 13G filing	SC 13G/A	Other	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0000834237-21-002981.pdf 0000834237-21-002981.rtf
Jan 29, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-21-000004.pdf 0001103021-21-000004.rtf 0001103021-21-000004.xls
Jan 29, 2021	Statement of changes in beneficial ownership of securities	4	3,4,5	BIODELIVERY SCIENCES INTERNATIONAL INC	View HTML 0001103021-21-000006.pdf 0001103021-21-000006.rtf 0001103021-21-000006.xls

Data provided by Kaleidoscope.

Recent BDSI News

BioDelivery Sciences Reports Solid Third Quarter 2021 Results November 3, 2021

Total Net Revenue of $41.1 Million , an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07 , EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential ...

BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer October 21, 2021

RALEIGH, N.C. , Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial ...

BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021 October 20, 2021

RALEIGH, N.C. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of ...

More news

More events

Stay Connected

Stay up to date on the latest news

Get started now